TY - JOUR
TI - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
AU - Dimopoulos, M.A.
AU - Moreau, P.
AU - Terpos, E.
AU - Mateos, M.V.
AU - Zweegman, S.
AU - Cook, G.
AU - Delforge, M.
AU - Hájek, R.
AU - Schjesvold, F.
AU - Cavo, M.
AU - Goldschmidt, H.
AU - Facon, T.
AU - Einsele, H.
AU - Boccadoro, M.
AU - San-Miguel, J.
AU - Sonneveld, P.
AU - Mey, U.
AU - EHA Guidelines Committee
AU - ESMO Guidelines Committee
JO - Annals of Oncology
PY - 2021
VL - 32
TODO - 3
SP - 309-322
PB - Elsevier Ireland Ltd
SN - 0923-7534, 1569-8041
TODO - 10.1016/j.annonc.2020.11.014
TODO - antineoplastic agent;  bortezomib;  busulfan;  carfilzomib;  cyclophosphamide;  dexamethasone;  doxorubicin;  lenalidomide;  melphalan;  prednisone;  thalidomide, Article;  autologous stem cell transplantation;  cancer diagnosis;  cancer incidence;  cancer radiotherapy;  cancer staging;  cancer survival;  cancer therapy;  consolidation chemotherapy;  differential diagnosis;  epidemiological data;  follow up;  graft versus host reaction;  human;  long term care;  maintenance therapy;  multiple myeloma;  personalized medicine;  plasma cell leukemia;  plasmacytoma;  practice guideline;  relapse;  risk benefit analysis;  treatment response;  follow up;  medical society;  multiple myeloma;  practice guideline, Follow-Up Studies;  Humans;  Multiple Myeloma;  Societies, Medical
TODO - null
ER -